Nantahala Capital Takes 9.9% Stake in Unicycive Therapeutics

TL;DR

**Nantahala Capital just revealed a 9.9% stake in Unicycive Therapeutics, signaling a big institutional bet.**

AI Summary

Nantahala Capital Partners Limited Partnership, a Massachusetts-based investment firm, reported acquiring shared voting and dispositive power over 2,121,753 shares of Unicycive Therapeutics, Inc. common stock, representing 9.9% of the company's outstanding shares. This significant stake was established as of September 29, 2023, and filed on February 5, 2024. This matters to investors because a large institutional investor now holds a substantial portion of Unicycive, potentially signaling confidence in the company's future or an intent to influence its direction.

Why It Matters

A major institutional investor now owns a significant portion of Unicycive, which could influence future strategic decisions or provide a vote of confidence in the company's prospects.

Risk Assessment

Risk Level: low — This filing indicates a significant institutional investment, which is generally seen as a positive or neutral development, not increasing risk.

Analyst Insight

A smart investor would research Nantahala Capital's investment history and Unicycive's recent performance and news, considering this significant institutional stake as a potential positive signal for the stock.

Key Numbers

• 2,121,753 — Shares Beneficially Owned (Represents the total shares Nantahala Capital has shared voting and dispositive power over in Unicycive Therapeutics.)
• 9.9% — Percentage of Class Outstanding (Indicates the significant portion of Unicycive Therapeutics that Nantahala Capital now controls.)

Key Players & Entities

• Nantahala Capital Partners Limited Partnership (company) — reporting person, investor
• Unicycive Therapeutics, Inc. (company) — subject company, issuer
• 2,121,753 (dollar_amount) — shares beneficially owned
• 9.9% (dollar_amount) — percentage of class outstanding
• September 29, 2023 (date) — date of event requiring filing
• February 5, 2024 (date) — filing date

Forward-Looking Statements

• Nantahala Capital Partners Limited Partnership may seek to engage with Unicycive Therapeutics' management or board to influence strategic decisions. (Nantahala Capital Partners Limited Partnership) — medium confidence, target: Within 12 months
• The significant institutional ownership could attract other institutional investors to consider Unicycive Therapeutics. (Unicycive Therapeutics, Inc.) — medium confidence, target: Within 6 months

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• tm245149d1_sc13g.htm (SC 13G) — 37KB
• 0001104659-24-010271.txt ( ) — 39KB

(a)

Item 1(a). Name of Issuer: UNICYCIVE THERAPEUTICS, INC. (the “Issuer”).

(b)

Item 1(b). Address of the Issuer's Principal Executive Offices: 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS, CA 94022

(a)

Item 2(a). Name of Person Filing NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP (“Nantahala”)

(b)

Item 2(b). Address of Principal Business Office or, if None, Residence: 130 Main St. 2 nd Floor New Canaan, CT 06840

(c)

Item 2(c). Citizenship: Nantahala is a Massachusetts limited partnership.

(d)

Item 2(d). Title of Class of Securities: Common Stock, par value $0.001 per share (the “Shares”).

(e)

Item 2(e). CUSIP Number: 90466Y103 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E). (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F). (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G). (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3). (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J). CUSIP NO. 90466Y103 Page 4 of 6 Item 4.

(a)

Item 4(a). Amount Beneficially Owned: As of February 5, 2024, Nantahala may be deemed to be the beneficial owner of 2,121,753 Shares. The 2,121,753 Shares includes 37,532 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.

(b)

Item 4(b). Percent of Class: As of February 5, 2024, each of the Reporting Persons may be deemed to be the beneficial owner of 6.1% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10-Q filed November 14, 2023, there were 34,754,401 Shares outstanding in addition to the 37,532 Shares issuable upon the exercise of the warrants).

(c)

Item 4(c). Number of shares as to which such person has: NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP (i) Sole power to vote or direct the vote 0 (ii) Shared power to vote or to direct the vote 2,121,753 (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of 2,121,753 CUSIP NO. 90466Y103 Page 5 of 6 Item 5. This Item 5 is not applicable. Item 6. This Item 6 is not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: This Item 7 is not applicable. Item 8. Identification and Classification of Members of the Group: This Item 8 is not applicable. Item 9. Notice of Dissolution of Group: This Item 9 is not applicable. Item 10. Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11. CUSIP NO. 90466Y103 Page 6 of 6

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct. Date: February 5, 2024 NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP By: /s/ Taki Vasilakis Taki Vasilakis Chief Compliance Officer Nantahala Capital Management, LLC /s/ Wilmot B. Harkey Wilmot B. Harkey /s/ Daniel Mack Daniel Mack

View Full Filing

View this SC 13G filing on SEC EDGAR